April 4th 2025
Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies
April 3rd 2025
Lumen Bioscience’s, LMN-201, was considered safe and well-tolerated and there were no severe dose-related or serious adverse events reported.
February 6th 2025
Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.
January 24th 2025
Nature Medicine published additional data on Vedanta Biosciences’ Clostridioides difficile investigational therapy, VE303, from its phase 2 trial.
January 8th 2025
CEO Larry D Sutton, MD, PhD, elaborates on the company's strategy and the science behind SIDIPREV to prevent C difficile infections in hospitalized patients.
Use of Fecal Microbiota Transplantation (FMT) Treatment in CDI
Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.
Watch
Challenges in the Management of CDI
Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.
Microbiome Composition Changes After C diff Treatment
A new study showed an introduction of beneficial microbiota.
Read More
Invasive Fungal Infections in Critically Ill COVID-19 Patients
Antifungal therapy was frequently initiated before essential diagnostic elements confirmed invasive fungal infections in critically ill COVID-19 patients.
C Diff Therapeutic is Efficacious, Safe in Immunocompromised Patients
Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.
Study Doesn’t Support Extending CDI Treatment in Patients on Concurrent Antibiotics
Investigators in Canada found no evidence to support extending treatment for Clostridioides difficile infection for patients on concurrent antibiotics
Real World Study Looking at Safety, Efficacy of C diff Therapeutic
Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.
Diagnosis of C difficile Infection (CDI)
Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.
Overview of Gut Microbiome
Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.
Oral Bacterial Therapy for Recurrent CDI Shows Promise in Phase 2 Trial
A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.
Specific Enzymes Found to Restrict the Growth of C difficile
The findings of this study could pave the way for new, disease-targeted probiotics.
Uptick in rCDI Coincided with COVID-19, According to New Analysis
Data from New Haven County, Connecticut, suggests the pandemic might have hurt efforts to curb recurrent CDI.
CREating New Strategies for the Treatment of Resistant Gram-Negative Infections
This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.
Earth Day 2023: Climate Change and Infectious Disease
The floods, heat waves, droughts, and other calamities caused by excessive greenhouse gas emissions also make us more vulnerable to ill effects of pathogens such as bacteria, viruses, plants and fungi.
C Diff Advocacy Organization Prepares for its Summit
The Peggy Lillis Foundation will host its summit on Monday and has a number of speakers who will discuss topics related to this healthcare-associated infection (HAI).
CDI Remains a Major, ‘Multifactorial’ Challenge
While efforts to curb in-hospital infection seem to have paid off, community-acquired cases appear headed in the opposite direction.
From Lettuce Recalls to New Moderna Vaccines: This Week’s Top 5 Stories
Catch up with this week's 5 most-read infectious disease stories.
Decreasing Inappropriate Antibiotic Prescribing for Viral Upper Respiratory Infections
Reducing unnecessary antibiotic prescriptions for viral upper respiratory tract infections is crucial to stop the spread of antimicrobial resistance.
Vancomycin as Secondary Prophylaxis to Prevent Recurrent C diff Infection
2 CDI recurrences occurred in this study, both in placebo recipients who were immunocompromised.
Can Utilizing an Electronic Health Record Improve C difficile Patient Outcomes?
This study implemented an Electronic Health Record in a major hospital system to catch otherwise undetected C diff infections.
SHEA Publishes Updated Resource to Prevent CDI in Healthcare Settings
The epidemiology society worked with a few medical organizations to update the guidance to limit infections.
Determining Incidence Rates of C diff and Recurrence in the Pediatric Population
A study looking at 5 years of data showed a decrease in the amount of cases, but with some important trends to be aware of in this population.
The Week's Top Stories: Breakthrough COVID, FDA Approvals, and More
This week's most-read stories discussed unforeseen consequences of the COVID-19 pandemic, including an increase in gastrointestinal diseases and a decrease in childhood asthma diagnoses.
Utilizing Oral Vancomycin for Clostridioides Difficile Prophylaxis
Investigators reviewed the current literature on the utility of oral vancomycin prophylaxis (OVP), and offered guidance for when this approach may be beneficial.
The Harms of Inappropriate Antibiotic Prescribing
A study demonstrated patients were frequently prescribed broad-spectrum antibiotics when more narrowly tailored antibiotics were considered the optimal choice.
COVID-19 News Update: The Top 5 Stories This Week
Yesterday, the FDA took a major step toward officially approving Paxlovid. Catch up on this story and the other top COVID-19 news updates from the past week.
Diet of Mother’s Milk Versus Formula Has No Effect on Preterm Infant Microbiome
For preterm infants, clinical outcomes from microbial mechanisms are not affected by a diet of only human milk compared to bovine milk formulas or fortifiers.
CDI Risk Higher for People with COVID-19
The investigators found the risk of hospital-acquired Clostridioides difficile (CDI) infection increased when a hospital switched to serving only coronavirus disease 2019 patients.
Discovering Metabolic Secrets of Anaerobes Provides a Better Understanding of C diff
Investigators see a potential new approach to therapeutic development for C diff.
Enterococci Enhances the Severity of Gastrointestinal Infections
Enteric pathogens increase C difficile virulence by providing amino acids that shape the metabolic environment in the gut.